Buy BRVE on BHB-1839's Differentiated Therapeutic Window in Non-Obstructive HCM
Braveheart Bio's BHB-1839 looks like a differentiated small-molecule myosin inhibitor for non-obstructive hypertrophic cardiomyopathy (HCM). With a market cap of $1.73B, insider buying at the IPO, and early Phase 2 data that support a favorable therapeutic window, there is a tactical long opportunity with defined risk. Entry $19.24, target $32.00, …